Double blind placebo controlled study to assess the expression of IgE [immunoglobulin E] on basophils and dendritic cells during omalizumab treatment
Phase of Trial: Phase IV
Latest Information Update: 01 Jul 2011
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Pharmacodynamics
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 01 Jul 2011 Last checked against ClinicalTrials.gov record.
- 26 Aug 2010 Results published in Respiratory Medicine.